PRF Technologies (PRFX) Income towards Parent Company (2020 - 2024)
PRF Technologies' (PRFX) quarterly Income towards Parent Company came in at -$7.6 million in Q2 2024, down 204.12% YoY from $7.3 million in Q3 2023, and down 30.63% on a QoQ basis from -$5.8 million in Q1 2024.
PRF Technologies (PRFX) Income towards Parent Company (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has 5 years of Income towards Parent Company data on file, last reported at -$7.6 million in Q2 2024.
- Quarterly Income towards Parent Company fell 204.12% year-over-year to -$7.6 million in Q2 2024, while the trailing twelve-month figure through Dec 2025 was -$7.6 million (up 68.54% YoY) and the FY2025 annual result came in at -$5.0 million, up 66.16% from the prior year.
- Income towards Parent Company declined to -$7.6 million in Q2 2024, from -$5.8 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$132000.0 in Q1 2020 to a low of -$10.7 million in Q4 2023.
- A 5-year average of -$3.6 million and a median of -$2.3 million in 2021 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2021 — Income towards Parent Company slumped 1606.06% — and 2023, when it surged 31.46%.
- Tracing PRFX's Income towards Parent Company over 5 years: stood at -$4.2 million in 2020, then plunged by 65.42% to -$6.9 million in 2021, then declined by 28.75% to -$8.9 million in 2022, then dropped by 21.01% to -$10.7 million in 2023, then climbed by 29.24% to -$7.6 million in 2024.
- The last three Income towards Parent Company figures came in at -$7.6 million (Q2 2024), -$5.8 million (Q1 2024), and -$10.7 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | PRF Technologies | 647,973.00 | -3.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7.60 Mn |
| Mar 31, 2024 | -5.82 Mn |
| Dec 31, 2023 | -10.74 Mn |
| Sep 30, 2023 | -1.60 Mn |
| Jun 30, 2023 | -2.50 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Sep 30, 2022 | -2.34 Mn |
| Jun 30, 2022 | -2.08 Mn |
| Mar 31, 2022 | -1.91 Mn |
| Dec 31, 2021 | -6.89 Mn |
| Sep 30, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.88 Mn |
| Mar 31, 2021 | -2.25 Mn |
| Dec 31, 2020 | -4.17 Mn |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | -148,000.00 |
| Mar 31, 2020 | -132,000.00 |